great volume today thus far -- PLBI Bid: 0.02 Ask: 0.023 Last: 0.023 Chg ($): 0.013 Vol: 11,547,760
TheGreenGiant
posted
PLBI-REGENOBODY S.A., a wholly owned subsidiary of Proton Laboratories, Inc., brings the benefits of bioscience to patients who have been diagnosed with chronic debilitating diseases, offering viable, efficient therapeutic options with special Stem Cell Therapies utilizing the most potent cells in the world, today. Therapies are tailored for each individual, based upon their specific needs. Cells are obtained by the most modern technologic method. Their transplant physicians and stem cell laboratory scientists, in conjunction with RNL Bio, have been regarded as the best in the world. Stem cells derived from Autologous (Stem cells taken from your own body) and Allogeneic (Stem cells from a source other than your own) are used depending on the particular condition that needs to be treated. Treatments are delivered by an experienced team of International and U.S. Board Certified Physicians who are guided by strict protocols ensuring excellence in medical care.
REGENOBODY IS A WORLD LEADER IN STEM CELLS TREATMENTS
By applying the regenerative powers of stem cells, REGENOBODY AGE REVERSAL achieves the target of halting the ageing degenerative process, improving the quality of life of people willing to maintain a young look and a real rejuvenation in the inside, with better functioning, re-energized and healthy organs.
REGENOBODY THERAPEUTIC brings the benefits of bioscience to patients who have been diagnosed with chronic debilitating diseases, offering viable, efficient therapeutic options.
Many different conditions can be successfully addressed using their special Stem Cell Therapies. Their institute utilizes the most potent cells in the world, today. Therapies are tailored for each individual, based upon their specific needs. Cells
TheGreenGiant
posted
PROTON LABORATORIES, INC. (PLBI) Proton Laboratories, Inc., through the acquisition of Regenobody S.A., a Dominican Republic company, is involved in some of the latest technologies associated with stem cell regeneration using the patient's own stem cells. Recent Price Last 0.01 Market Capitalization $1.08M Est Float 36M Outstanding Shares 56M Quotation OTC.PK
· Stem Cell Therapy International, Inc. is a development-stage company. The Company is engaged in the licensing of stem cell technology, the sale of stem cell products, and the referral of patients to affiliated stem cell clinics through its wholly-owned subsidiary Stem Cell Therapy International Corp. OTCBB:SCII Recent Price: $.112 · International Stem Cell Corporation, incorporated is a biotechnology company. The Company is focused on developing therapeutic products and research products. It is in development-stage. The Company’s objective is to create an unlimited source of human cells for use in the treatment of several diseases, including diabetes, liver disease, corneal disease, and retinal disease through cell transplant therapy. OTCBB: ISCO Recent Price: $.83
JFPENNY
posted
PLBI, Keep this one on your radar list. News came out after the close yesterday and this morning had some nice prebuys. This is going to have some nice volume and some nice gains today. Good news make this one fly. This afternoon this is going to explode. Take a position while the price is still low. Good luck here is the latest news..
SOSUA BAY, Dominican Republic, May 11, 2010 (GLOBE NEWSWIRE) -- Proton Laboratories, Inc. (Pink Sheets:PLBI - News) announced today that following its success in attaining exclusive rights for RNL Bio Company Ltd's licenses, technology and equipment which allows PLBI's wholly owned subsidiary, RegenoBody, S.A. to treat anyone within the Caribbean, Central and/or South America, that the laboratory needed to perform the work is being designed by RNL Bio for shipment to the RegenoBody facility in the Dominican Republic. The laboratory will be designed according to the specifications required of RNL Bio in Korea so that it can duplicate the success of RNL Bio in regenerating human stem cells.
The initial concept of bringing what was once stereotyped as a controversial treatment to this hemisphere was based upon more than a year of research and the actual treatment and successful results of PLBI's President, Armando Casciati. After Mr. Casciati's treatment, he acquired the majority control of PLBI.pk, in an effort to accelerate the process of bringing stem cell technology to the Western Hemisphere.
Mr. Casciati stated, "Entrepreneurs typically look merely for profit opportunities. I am proud to have found such an incredible life opportunity which will help serve the public with some of the latest technological advances in medical history. I believe our alliance with RNL Bio Company will prove to be a life changing opportunity for our clients, as it has been for me."
RNL Bio Company LTD is considered a leader in stem cell technology with a wealth of treatments. After years of investment and research, RNL has developed technology ranging from cosmetic and arthritic needs to spinal cord injury and cancer treatments.
Korean FDA approved RNL's human clinical study to treat patients with spinal cord injury using 'RNL-Astrostem' that is based on fat derived adult stem cells.
In early 2009, RNL Bio publicly presented its three years' preclinical trial results showing a perfect safety profile and remarkable efficacy potential. RNL was approved by the Korean government to begin phase I human trial using these adult stem cells and we believe it is the world's first trial to treat spinal cord injury with adult stem cells derived from a patients' own fat tissue.
Since the Korean FDA approval, RNL Bio has progressively increased the utility of its RNL-Astrostem technology. RNL-Astrostem is administered by intravenous infusion so patients don't have to worry about any invasive and painful surgical procedure. Dr. Jeong Chan Ra, CEO of RNL Bio, said, "Our stem cell therapeutics involves no immune rejection because the stem cells are exactly the patient's own. Our adult stem cell has no tumorigenicity activity at all while embryonic stem cell faces high risk of it. We have developed the safest therapeutics to help devastated patients with incurable diseas
posted